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Abstract 
Obesity is an epidemic chronic disease which is a risk factor for a number of serious medical conditions. Intragastric 
balloon, as an alternative, non-surgical treatment approach for the management of obesity, was rejected in previous 
evidence-based reviews. The object of this review is updating the data and confirming the safety and efficacy of the 
procedure. In this review, systematic literature retrieve of MEDLINE, EMBASE, CENTRAL and other information sources 
was performed from inception to December 2014. The quality of selected studies was assessed and meta-analyses of 
weighted mean differences were made using the inverse variance method. Meta-analyses presented significant effect 
sizes of −8.9 kg, −3.1 kg/m2 and −21.0% for SMG as well as of −1.5 kg and −1.2 kg/m2 for LSG, favoring the interven-
tion group. Safety analysis showed that minor complications occurred at a high rate in intervention group, however, 
no serious or fatal complication was reported in these studies. In conclusion, the current review presents that short-
term efficacy for 6 months treatment of intragastric balloon in association with conservative therapy is clinically 
significant.
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Background
Obesity is a chronic disease which is a risk factor for a 
number of serious medical conditions such as diabe-
tes mellitus, cardiovascular diseases, cancers, and some 
other obesity-related diseases [1] and leads to consider-
able morbidity, substantial mortality and impaired qual-
ity of life [2–4]. The World Health Organization’s (WHO) 
latest projection indicated that there were more than 
1.9 billion overweight adults and at least 600 million 
people who were obese in 2014. And by 2015, the num-
bers would be approximately 2.3 billion and 700 million 
respectively [5].
According to current guidelines, options for treatment 
include behavioral modification (which include physi-
cal exercise, dietary modification, caloric restriction and 
psychosocial interventions), pharmacotherapy (such as 
orlistat), and bariatric surgery. As systematic reviews 
[6, 7] have shown that it is the most effective way to 
achieve sustained weight reduction, bariatric surgeries 
are suggested for the patients who failed in non-surgical 
interventions and who have severe obesity or moder-
ate obesity with a major obesity-related comorbidity 
[8]. However, as the substantial co-morbidities, serious 
adverse effects and high surgical risks, there is a part of 
obese objects (especially adolescents, who have been 
more attention paid in recent years) who does not qualify 
for, or does not give consent to, the bariatric procedure.
As a minimally invasive procedure inducing weight 
loss by reducing the gastric reservoir capacity, leading to 
premature satiation and prolonged satiety, and regulating 
hormone mediated signal transduction, intragastric bal-
loon (IGB) insertion performs an alternative, non-surgi-
cal treatment approach for the management of obesity in 
those individuals who refuse or are unsuitable for bariat-
ric surgeries.
Open Access
*Correspondence:  jiliver@vip.sina.com 
†Yiyuan Zheng and Miao Wang contributed equally to this work and 
should be considered co-first authors.
2 Institute of Digestive Diseases, Longhua Hospital, Shanghai University 
of Traditional Chinese Medicine, Shanghai 200032, China
Full list of author information is available at the end of the article
Page 2 of 9Zheng et al. J Transl Med  (2015) 13:246 
The procedure has first been performed in the early 
1980s [9] as one of the earliest devices used for endo-
scopic bariatric intervention and continued to become 
a worldwide epidemic in recent years. Some systematic 
reviews [10, 11] have been published during the period, 
however, different results were turned out which leads to 
a confusing conclusion.
In these two reviews, the early one [10] which obtained 
a positive consequence used a quite broad inclusion cri-
teria. Plenty of cohort studies and just two controlled tri-
als were included in this review which means the validity 
of this research could be limited in somehow. And the 
later one [11], which used a rigorous inclusion criteria 
and performed a series of quality assessments, turned 
out a negative consequence as the small numbers of trials 
within any component comparisons.
However, both of these two reviews were accomplished 
several years ago. In recent years, ongoing innovations 
have resulted in newer designs and placement techniques 
which improve the efficacy as well as reduce adverse 
reactions. Hence, with a growing body of evidence sup-
porting the safety and short-term efficacy of the proce-
dure, we decided to make an update to confirm it as well 
as made a review of the current status of Intragastric Bal-
loon to increase knowledge, foster research, and promote 
better treatment for people with obesity and their loved 
ones.
Methods
Search strategy and study selection
An electronic literature search was performed on OVID 
with the following databases: MEDLINE, EMBASE, 
CENTRAL. The search strategy followed the identifica-
tion and screening guidelines established by the Preferred 
Reporting Items for Systematic Reviews and Meta-Analy-
ses (PRISMA) statement [12] without language and pub-
lication restrictions was presented in Additional file  1: 
Appendix. The search was supplemented by screening 
other databases such as Center Watch, Clinical Trials 
and Current Controlled Trials. Manual retrieval of the 
reference lists of selected papers and relevant systematic 
reviews complemented the electronic search.
The inclusion criteria were summarized as randomized, 
parallel controlled clinical trials comparing the efficacy 
and safety of intragastric balloon with conservative ther-
apy were potentially eligible. The updated articles were 
selected when double or serial publications were found 
by the same research group to avoid double counting 
objects. Trials satisfied the inclusion criteria were also 
excluded as there is no available data. Each record was 
independently assessed by two researchers and conflicts 
resolved by a third investigator.
Data extraction and quality assessment
A standard data extraction method was conformed in 
each trial to record the following properties: study char-
acteristics (including year of publication, country and 
sample size); demographic and anthropometric measures 
(age, gender and BMI); intervention therapy; compari-
son therapy and outcomes. Outcomes include efficacy 
indicators [weight loss (WL), BMI and excess weight 
loss (EWL)] and safety indicators (abdominal pain, flatu-
lence, nausea, vomiting, gastric erosion and gastric ulcer) 
were extracted at the time points of end-of-treatment 
for which data were available as well as at the post clos-
est time points for which were not. Data were combined 
using weighted means and standard deviations as inter-
vention group versus comparison group while there is 
more than one controlled parallel-arm in a trial. Each 
trial was independently extracted by two reviewers and 
checked each other for accuracy.
The quality of trials was assessed using the following 
evidence-based parameters: randomization technique, 
blinding design, method of allocation concealment, 
descriptions of attrition, preliminary analysis, intention-
to-treat (ITT) analysis and report of adverse events. 
Finally, we evaluated a Jadad scale score [13] to assess the 
risk of study bias. However, the score was not used as a 
criterion for selection of trials, whereas some parameters 
were used only for descriptive purposes. Two reviewers 
independently assessed each study. Disagreements were 
resolved by a third one.
Data synthesis and analysis
Data manipulation and analysis were performed using 
Comprehensive Meta-Analysis Version 2 in conjunction 
with Excel 2013 [14].
Results were calculated by weighted mean differences 
(WMDs) and associated 95% confidence intervals (CIs). 
Subgroup analysis were performed, grouping by the 
treatment time whether less than six  months or not as 
less than six months group (LSG) and six months group 
(SMG) to explore the relationship between efficacy and 
treatment time. For adverse events, we just reported the 
incidences of adverse events occurred during the period 
of treatment. No meta-analysis was performed for low 
comparability as sham procedure was not performed in 
most comparison groups. Mixed effects analysis models 
were applied throughout which means random effects 
models were used to combine studies within each sub-
group and fixed effects models were used to combine 
subgroups and yield the overall effects.
Heterogeneities were estimated using the I2 statistics, 
which indicated the per cent of total variations (within- 
and between-study) due to between-study variations. 
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I2 < 33.3% was considered as an indication of low heter-
ogeneity, 33.3% ≤  I2 < 66.7% was considered as an indi-
cation of medium heterogeneity, and I2  ≥  66.7% was 
considered as an indication of high heterogeneity.
Publication biases were explored by using the Begg and 
Mazumdar adjusted rank correlation test as well as by 
using the classic fail-safe N method. One study removed 
analyses were performed to evaluate sensitivities of 
effects. Funnel plots and meta-regressions were not per-




The results of the literature retrieve and selection pro-
cess are presented in Fig. 1. A total of 690 records were 
identified, in which 625 were retrieved through elec-
tronic database and 65 were supplied by other infor-
mation sources. 223 duplicates were removed. After 
screening by title and abstract, we read the full-text of 
the remaining 36 articles. Nine were rejected as cross-
over studies of three as well as not RCT designs of 6 and 
11 were excluded because there’s no available data. As 
Fig. 1 PRISMA flowchart for the selection of studies. Outcomes of the systematic review of the literature by record identification, screening, and 
analysis in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement flow diagram.
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removement of five double or serial publications, a final 
of 11 studies [15–25] were included for quantitative 
analysis.
Characteristics of the 11 included studies are described 
in Table  1. Comparative publications were published 
between 1987 and 2014. Sample size ranged from 22 to 
128 (median 36), the mean age for which data were avail-
able ranged from 35 to 46  years (median 42  years) and 
the baseline average BMI ranged from 35.0 to 50.4 kg/m2 
(median 41.8 and 43.1 kg/m2). Of the 11 trials, nine com-
pared intragastric balloon in association with conserva-
tive therapy (behavioral modification in all of them and 
pharmacotherapy plus in just one object) and conserva-
tive therapy only, and the other three compared intragas-
tric balloon and observation without any treatment. Five 
blind studies got sham procedures in comparison group 
and the others didn’t. The numbers of trials divided into 
LSG and SMG were 5 and 6 respectively. Finally, quality 




Figure 2a presents the effect sizes of eight trials for which 
information are available on WL. The WMD comparing 
intervention group and comparison group was −1.5  kg 
[(−2.0, −1.1), p < 0.01] for LSG, favoring the intervention 
group; whereas, the corresponding WMD for SMG was 
−8.9 kg [(−10.3, −7.5), p < 0.01].
Within-group analysis indicated low heterogene-
ity (I2  <  0.1) in LSG as well as medium heterogeneity 
(I2 =  43.3) in SMG. Significant heterogeneity (p < 0.01) 
was found between LSG and SMG.
No publication bias was found using the Begg and 
Mazumdar adjusted rank correlation test (p  =  0.54) as 
well as using the classic fail-safe N method (n  =  519). 
One study removed analysis showed an overall WMD 
of −3.0  kg with stable results (WMDs ranged between 
−2.4 and −3.0) of seven studies except Geliebter (1991) 
(WMD = −7.9 kg) using fixed model. However, the cor-
responding analysis showed an overall WMD of −6.4 kg 
with stable results (WMDs ranged between −5.5 and 
−7.4) of all the eight studies using random model.
BMI
Figure  2b presents the effect sizes of seven trials for 
which information are available on BMI. The WMDs 
comparing intervention group and comparison group 
were −1.2 kg/m2 [(−2.1, −0.3), p = 0.01] and −3.1 kg/m2 
[(−3.9, −2.3), p  <  0.01] for LSG and SMG respectively, 
favoring the intervention group.
Within-group analysis indicated low heterogene-
ity (I2  <  0.1) in LSG as well as medium heterogeneity 
(I2 =  61.0) in SMG. Significant heterogeneity (p < 0.01) 
was found between LSG and SMG.
No publication bias was found using the Begg and 
Mazumdar adjusted rank correlation test (p  =  0.13) as 
well as using the classic fail-safe N method (n  =  241). 
One study removed analysis showed overall WMDs of 
−2.9 and −2.4 kg/m2 with stable results (WMDs ranged 
between −2.5 and −3.1 as well as between −2.2 and 
−2.8) using fixed model and random model respectively.
Table 1 Characteristics of the 11 included studies
BMI body mass index, IGB intragastric balloon, NA not available, BM behavioral modification, NT no treatment, PT pharmacotherapy.








Time point,  
months
Lindor et al. (1987) [15] USA 22 25–51 9 >30 IGB Sham 3
Ramhamadany et al. (1989) 
[16]
England 24 NA 0 41 IGB + BM Sham + BM 3
Geliebter et al. (1991) [17] USA 86 NA 19 >40 IGB ± BM BM/NT 3
Martinez-Brocca et al. (2007) 
[18]
Spain 22 36 ± 10 23 50.4 ± 7.8 IGB Sham 4
Konopko-Zubrzycka et al. 
(2009) [19]
Poland 36 42 ± 12 47 47.2 ± 5.5 IGB + BM BM 6
Farina et al. (2012) [20] Italy 50 35 ± 1 22 41.8 ± 0.8 IGB + BM + PT BM + PT 12
Lee et al. (2012) [21] Singapore 21 21–65 61 31.5 ± 4.5 IGB + BM Sham + BM 6
Fuller et al. (2013) [22] Australia 66 46 ± 9 33 36.4 ± 2.6 IGB + BM BM 6
Ponce et al. (2013) [23] USA 30 41 ± 9 13 35.0 ± 2.6 IGB + BM BM 6
Mathus-Vliegen and  
Eichenberger (2014) [24]
The Netherlands 40 42 ± 11 10 43.1 ± 6.3 IGB Sham 3
Mohammed et al.  
(2014) [25]
Egypt 128 44 ± 9 58 47.7 ± 1.1 IGB + BM BM 6
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Excess weight loss (EWL)
Figure 2c presents the effect sizes of four trials for which 
information are available on EWL. None of them got 
treatment less than 6  months. The WMD comparing 
intervention group and comparison group were −21.0% 
[(−27.4, −14.6), p  =  0.01], favoring the intervention 
group.
No significant heterogeneity (p < 0.05) was found and 
medium heterogeneity (I2 = 62.6) was assessed according 
to the pre-specified I2 value.
No publication bias was found using the Begg and 
Mazumdar adjusted rank correlation test (p  =  1.00) as 
well as using the classic fail-safe N method (n  =  138). 
One study removed analysis showed overall WMDs of 
−19.9 and −21.0% with stable results (WMDs ranged 
between −18.6 and −21.3 as well as between −18.6 and 
−22.6) using fixed model and random model respectively.
Safety
As safety index, the incidences of adverse events 
occurred during the period of treatment are presented in 
Fig. 3. Of the 11 included comparative studies, 8 reported 
the relevant information which included 6 complica-
tions (nausea, abdominal pain, vomiting, gastric ero-
sion, flatulence and gastric ulcer). For nausea, 122 events 
occurred in a total of 169 objects (72%) in intervention 
group; whereas, the corresponding number was 7 of 115 
(6%) for comparison group. 80 of 159 (50%) and 2 of 
117 (2%) were reported in intervention and comparison 
group respectively for abdominal pain as well as 78 of 
202 (39%) and 4 of 160 (3%) for vomiting. Complications 
were reported as 27 of 85 (32%), 31 of 127 (24%) and 7 of 
138 (5%) for gastric erosion, flatulence and gastric ulcer 
in intervention group, respectively. In comparison group, 
no gastric erosion or ulcer was found and flatulence hap-
pened in four individuals of 91 objects (4%). One brief 
hypoxia during device removal was reported in Ponce 
(2013) and no other fatal event such as gastric-intestinal 
perforation or intestinal obstruction was reported in 
these studies.
Discussion
The current review systematically identified and assessed 
a wide range of evidence regarding the efficacy and safety 
of intragastric balloon in association with conservative 
therapy versus conservative therapy only. As the initial 
post balloon placement effect (such as significant nausea 
and vomiting) would result in immediate self-unmasking 
for those patients randomized to the treatment group, 
most trials didn’t perform blind design. No-blinding 
studies leading to low quality assessment were not 
excluded because the small number of available trials.
Meta-analyses presented significant effect sizes of 
−8.9 kg, −3.1 kg/m2 and −21.0% for SMG as well as of 
Table 2 Quality assessment of included studies










Lindor et al. (1987) 
[15]
Yes Unclear Yes Yes Yes No Yes 4
Ramhamadany et al. 
(1989) [16]
Yes Yes Yes Yes Yes Yes Yes 5
Geliebter et al. (1991) 
[17]
Yes Unclear No Yes Yes Yes Yes 2
Martinez-Brocca  
et al. (2007) [18]
Yes Unclear Yes Yes Yes No Yes 5
Konopko-Zubrzycka 
(2009) [19]
Yes Unclear No Yes Yes Yes Yes 2
Farina et al. (2012) 
[20]
Yes Unclear No Yes Yes No Yes 2
Lee et al. (2012) [21] Yes Yes Yes Yes Yes No No 4
Fuller et al. (2013) 
[22]
Yes Yes No Yes Yes Yes Yes 3
Ponce et al. (2013) 
[23]




Yes Yes Yes Yes Yes Yes No 4
Mohammed et al. 
(2014) [25]
Yes Unclear No Yes Yes Unclear Yes 2
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−1.5 kg and −1.2 kg/m2 for LSG, favoring the interven-
tion group. As a modest weight loss of 5–10% is asso-
ciated with clinically significant benefits reducing the 
risk of diabetes, hyperlipemia, hypertension and asso-
ciated cardiovascular diseases [26–28], standards were 
confirmed as −5  kg, −2  kg/m2 and −15% for mod-
est efficacy as well as −10 kg, −4 kg/m2 and −25% for 
obvious efficacy. According to these standards, mod-
est efficacy for intragastric balloon as a conjunction 
therapy to conservative therapy was achieved in SMG. 
Fig. 2 Forest plots for effects of intragastric balloon in association with conservative therapy. a Forest plot for SMD of WL in intervention group 
compared with comparison group. b Forest plot for SMD of BMI in intervention group compared with comparison group. c Forest plot for SMD of 
EWL in intervention group compared with comparison group.
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As conservative treatments were performed in most 
individuals of comparison groups, clinically significant 
benefits for 6 months treatment of intragastric balloon 
in association with conservative therapy could be con-
firmed conservatively. However, no clinically signifi-
cant benefit was found in LSG which was likely due to 
the small number of trials and the heterogeneity of the 
studies in each group.
Subgroup analyses indicated that heterogeneity 
between long-term and short-term treatment was exactly 
significant. Combined with previous analyses, the effi-
cacy of long-term treatment presented a superiority to 
short-term treatment. These results suggested that for 
improved efficacy, balloon treatment might need to be 
longer according to the individual’s gastric tolerance. 
However, as researches reported long-term placement 
was associated with a trend towards greater procedure- 
and device-related complications, the treatment time 
should not be much longer than 6 months.
High heterogeneity was found as most was due to 
between-group differences. Within-group analysis 
showed low heterogeneity in LSG as well as medium het-
erogeneity in SMG. However, attention should still be 
paid as the validity of tests was limited with small num-
ber of trials in each analysis. Differences in material, vol-
ume of balloons, patient characteristics, and especially in 
treatment of conservative therapy were potential sources 
for heterogeneity. Analyses were not performed for the 
same reason as small numbers of trials.
No publication bias was found using the Begg and 
Mazumdar adjusted rank correlation test as well as using 
the classic fail-safe N method in all analyses which indi-
cated a low risk of publication bias could be believed. It’s 
also an indicator of stable that much bigger classic fail-
safe N than the number of included studies. Sensitivity 
analyses showed stable results on the other hand except 
analysis of WL with Geliebter (1991) using fixed model, 
however, the corresponding analysis using random model 
was stable. Study was re-read and the reason was consid-
ered as rigorously controlled intervention inducing small 
variance in each group which resulted in a big weight 
and the combination of data went a step further on this 
way. However, the effect size excluded Geliebter (1991) 
was better than which included it and was still clinically 
significant.
Safety analysis showed that complications occurred at 
a high rate in intervention group. Fortunately, the com-
plications were all minor and most of them were self-
healing reactions which would disappear after a few 
days. In the meaning time, some researches [29–31] were 
committed to improving these conditions by develop-
ing new balloons or new placement techniques as well as 
by associating with other treatment such as antiemetic. 
Although some serious complications such as gastric-
intestinal perforation or intestinal obstruction were not 
reported in this review, it should be noted that there were 
some trials meeting these reactions [10, 32, 33].
Compared with the previous systematic reviews [10, 
11], a clinically significant benefit was verified which was 
due to a sufficient number of available studies. Inclusion 
criteria was rigorously designed, some previous included 
controlled trials were also excluded as the cross-over 
design studies used different program designs which 
might bring unstable results. Another important supe-
riority is that subgroup analysis for treatment time was 
performed in this review. It was also confirmed that the 
efficacy of long-term treatment presented a superiority to 
short-term treatment which was not disclosed in previ-
ous. In consideration of the complications, this research 
made a suggestion that for improved efficacy, the time of 
balloon treatment might need to be longer according to 
the individual’s gastric tolerance but should not be longer 
than 6 months.
Limitations should be acknowledged that the number 
of trials for subgroup analysis was small in each group 
and heterogeneity of the studies such as the models of 
balloons and the different conservative treatments was 
not analyzed. The most important is that analyses were 
just performed at the time points of end-of-treatment. 
Most long-term follow up studies were cohort stud-
ies and the randomized parallel controlled clinical trials 
were too less to analyze. What’s more, the efficacies of 
maintenance for long-term follow up were quite different 
in these trials. Some [34–38] reported that the treatment 
induced a successful weight loss and maintenance, a bet-
ter control of comorbidities and a better quality of life. 
Fig. 3 The incidences (%) of adverse events occured during the 
period of treatment. The adverse events included three major com-
plications (nausea, abdominal pain and vomiting) and three minor 
complications (gastric erosion, flatulence and gastric ulcer).
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However, others [39–41] reported that most patients lost 
the reduction after balloons were removed and the long-
term results were poor. According to studies [42–44] 
exploring the relationship between efficacy and various 
factors, the difference was considered as a result inducing 
by a series of factors such as compliance with long-term 
behavior modification, complications, and mental state.
In recent years, new balloons such as adjustable balloon, 
swallowable balloon, self-emptying balloon and dual intra-
gastric balloon (two connected balloons) were tested for 
improving effect or reducing complications [29, 30, 45, 46]. 
Repeated treatment with balloons was also researched, 
however, the outcomes were confused [47, 48]. A part of 
researches [49, 50] suggested that the procedure should be 
associated with some new methods such as psychotherapy 
and even endoscopic gastrointestinal bypass surgery (such 
as EndoBarrier gastrointestinal liner). Others [51–53] 
declared that intragastric balloon could be an approach 
smoothing the path to bariatric surgery.
In conclusion, as an alternative, non-surgical treatment 
approach for the management of obesity in those individ-
uals who refuse or are unsuitable for bariatric surgeries, 
the short-term efficacy has been verified in this review. 
However, more new designed, rigorously controlled and 
randomized long-term follow-up studies were needed to 
assess long-term efficacy and safety of the procedure.
Conclusions
The current review summarizes a wide range of evidence 
regarding the efficacy and safety of intragastric balloon 
in association with conservative therapy on weight loss 
in obese objects. Short-term efficacy for 6 months treat-
ment of intragastric balloon in association with conserv-
ative therapy is clinically significant.
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